We are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page or call 1-877-436-3683.
COMBINING THE ANTIBODIES YOU KNOW IN ONE FASTER MODE OF ADMINISTRATION1,2
*Refers to actual PHESGO injection time of ~5 minutes for the maintenance dose. The loading dose is ~8 minutes. This does not account for observation time and other aspects of treatment. Actual clinic time may vary.1
COMBINING THE ANTIBODIES YOU KNOW IN ONE FASTER MODE OF ADMINISTRATION1,2
*Refers to actual PHESGO injection time of ~5 minutes for the maintenance dose. The loading dose is ~8 minutes. This does not account for observation time and other aspects of treatment. Actual clinic time may vary.1
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) state that pertuzumab, trastuzumab and hyaluronidase-zzxf injection for subcutaneous use (PHESGO) may be substituted anywhere that IV pertuzumab (PERJETA) + trastuzumab are given as part of systemic therapy for HER2+ breast cancer.†3
†Pertuzumab, trastuzumab, and hyaluronidase-zzxf injection for subcutaneous use (PHESGO) has different dosing and administration instructions compared to the intravenous products.
Watch a video tutorial with instructions for preparing and administering PHESGO.
Explore the side effect profile for PHESGO vs PERJETA + trastuzumab.
Genentech is committed to trying to help patients access their Genentech medicine.
PHESGO Prescribing Information. Genentech, Inc. 2020.
PHESGO Prescribing Information. Genentech, Inc. 2020.
PERJETA Prescribing Information. Genentech, Inc. 2021.
PERJETA Prescribing Information. Genentech, Inc. 2021.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V2.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed January 21, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V2.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed January 21, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.